as 12-20-2024 3:41pm EST
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
Founded: | 1996 | Country: | United States |
Employees: | N/A | City: | AUSTIN |
Market Cap: | 6.3M | IPO Year: | N/A |
Target Price: | $13.50 | AVG Volume (30 days): | 90.1K |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -3.09 | EPS Growth: | N/A |
52 Week Low/High: | $0.93 - $2.67 | Next Earning Date: | 11-14-2024 |
Revenue: | $5,725,000 | Revenue Growth: | 52.63% |
Revenue Growth (this year): | 32.12% | Revenue Growth (next year): | -24.60% |
PSTV Breaking Stock News: Dive into PSTV Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Argus Research
13 days ago
Argus Research
14 days ago
Argus Research
17 days ago
Argus Research
18 days ago
GlobeNewswire
19 days ago
Argus Research
19 days ago
GlobeNewswire
20 days ago
The information presented on this page, "PSTV PLUS THERAPEUTICS Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.